Phio PharmaceuticalsPHIO
13F holders, Q3 2025 (September 30)11holders
3new positions
3sold out
$2.48avg. 13F price*
At the end of Q3 2025, 11 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings, unchanged from Q2 2025. 3 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($217K), Geode Capital Management, LLC ($144K) and Cetera Investment Advisers ($83K).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $2K |
| Exits | 3 | $42K |
All 13F filers, Q2 2025 → Q3 2025: 42,361 shares bought and 18,597 shares sold, net +23,764 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Vanguard Group Inc. | 0.00% | Add +80.1% | 87,628 | $217K |
| Geode Capital Management, LLC | 0.00% | Add +0.4% | 57,906 | $144K |
| Cetera Investment Advisers | 0.00% | Add +3.1% | 33,500 | $83K |
| Morgan Stanley | 0.00% | No change | 6,000 | $15K |
| Bank of America Corp. | 0.00% | Add +2943.5% | 1,400 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -42.3% | 1,101 | $3K |
| BNP Paribas Financial Markets | 0.00% | New | 413 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 406 | $1K |
| Assetmark, Inc. | 0.00% | No change | 110 | $273 |
| UBS Group AG | 0.00% | New | 13 | $32 |
| Activest Wealth Management | 0.00% | No change | 9 | $22 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.